Although the liver FGFR4 is silenced, the beneficial effects of FGF15/19 on liver steatosis may be due to its action via FGFR4 in the intestine or FGFR1 in the liver or adipose tissue. This evidence concerns the gene FGFR1 and Hepatic steatosis.